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Abstract
Parkinson disease (PD) is a chronic and neurodegenerative disease with motor and nonmotor symptoms. Multiple pathways 
are involved in the pathophysiology of PD, including apoptosis, autophagy, oxidative stress, inflammation, α-synuclein 
aggregation, and changes in the neurotransmitters. Preclinical and clinical studies have shown that melatonin supplementa-
tion is an appropriate therapy for PD. Administration of melatonin leads to inhibition of some pathways related to apoptosis, 
autophagy, oxidative stress, inflammation, α-synuclein aggregation, and dopamine loss in PD. In addition, melatonin improves 
some nonmotor symptom in patients with PD. Limited studies, however, have evaluated the role of melatonin on molecular 
mechanisms and clinical symptoms in PD. This review summarizes what is known regarding the impact of melatonin on 
PD in preclinical and clinical studies.
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Introduction
Parkinson disease is a chronic and neurodegenerative disease 
with motor (Swallowing disorder, speech disorder, bradykin-
esia, hypokinesia and tremor), and nonmotor (cognitive and 
sleep disorder) symptoms (Connolly and Lang 2014). Diag-
nosis of PD usually is occurred by the first motor symptoms 
Hughes et al. (2007). Swallowing problems is occurred in 
40–80% of the PD patients (Kalf et al. 2011). Speech dis-
order also is occurred in more than half of the PD patients 
(Perez-Lloret et al. 2012). In addition, cognitive impairment 
was noted in a quarter of the patients with PD without any 
dementia disorder (Aarsland et al. 2010). Patients with PD 
have low quality of life due to pain and depression (Balash 
et al. 2019). Decreased dopamine secreting and its neurons 
are apparent in the substantia nigra (SN) (Connolly and Lang 
2014). Up to 80% of dopaminergic neurons are lost before 
the revealing motor symptoms of PD (Chung et al. 2001). 
The dysregulation of cytosolic dopamine and reactive met-
als, especially iron, plays an essential role in pathogenesis of 
PD (Zucca et al. 2017). Oxidative stress, inflammatory fac-
tors, aquaporin 4, and apoptosis pathways seem to contribute 
to the pathophysiology of PD (Anglade et al. 1997; Jenner 
2003; Zucca et al. 2017; Hughes et al. 2007). The etiology 
of PD is multifactorial, and there is no definitive treatment 
that will stop development of the disease. Existing treat-
ments are symptomatic, aim of which is correcting the motor 
disorders. For example, levodopa is a standard drug and the 
most common treatment for patients with PD (Jankovic and 
Stacy 2007). However, it has been reported that it devel-
ops different complications on consuming levodopa in PD 
patients (Toth et al. 2008; Thanvi and Lo 2004). Today, ben-
eficial effects of different diets and supplements, including 
vitamins (Lima et al. 2018), medical plants (Venkatesh et al. 
2019; Mahboubi et al. 2016), probiotics bacteria (Borzabadi 
et al. 2018; Thanvi and Lo 2004; Tamtaji et al. 2019c), and 
melatonin (Delucca et al. 2018; Tamtaji et al. 2019a) were 
indicated in controlling PD or other age-related disorders.
Melatonin (N-acetyl-5-methoxy tryptamine) is best 
known for its synthesis within the pineal gland (Lerner 
et al. 1958). Melatonin is produced in mammals, unicellular 
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eukaryotes, plants, and bacteria (Slominski et al. 2012). 
Obviously many species that produce melatonin have no 
pineal gland. Melatonin exists widely in many types of food 
including meat, eggs, nuts, and medical herbs (Reiter et al. 
2001; Mercolini et al. 2012; Tan et al. 2003, 2014). Mela-
tonin precursor is l-tryptophan is converted to melatonin via 
four enzymes including N-acetyltransferase, N-acetylsero-
tonin methyltransferase, tryptophan hydroxylase, and l-aro-
maticamino acid decarboxylase (Tan et al. 2016). Function 
of melatonin often is triggered through interactions with its 
membrane receptors (MT1 and MT2) which are G protein-
coupled receptors (Dubocovich and Markowska 2005; Rep-
pert 1997; Hattori et al. 1995). Several physiological/patho-
logical conditions also change the morphology of the pineal 
gland (Grosshans et al. 2016; Bumb et al. 2014). The degree 
of pineal calcification might be an indicator of diminished 
ability of the pineal gland to produce melatonin. The reduced 
6-sulfatoxymelatonin excretion with age is associated with 
the increased pineal calcification (Kunz et al. 1999). There 
are calcium deposits in 21% and cysts in 59% of the glands 
in older men (Sigurdardottir et al. 2016). Calcified pineal 
volumes in various age groups are different (Beker-Acay 
et al. 2016). The changes of pineal gland lead to lower pin-
eal melatonin and B-cells in aging (Paltsev et al. 2016). In 
addition to melatonin, melatonin receptors drop with aging 
(Hill et al. 2013). Melatonin levels are also related to aging 
(Waldhauser et al. 1988).
The severe damping of a bioenergetic oscillatory pattern 
was seen in the fibroblasts of PD patients. Clock genes are 
deregulated in PD fibroblasts (Pacelli et al. 2019). Dysfunc-
tional circadian clock in PD is involved in abnormal antioxi-
dative response through SIRT1-dependent brain and muscle 
Arnt-like protein 1 (BMAL1) pathway (Wang et al. 2018). 
BMAL1 and rPer1 significantly decreased in PD patients 
(Cai et al. 2010; Mattam and Jagota 2015). The expres-
sion of BMAL1 in patients with PD has significant correla-
tion with disease severity (Cai et al. 2010). Per1 genes are 
changed in PD, which has important role in pathogenesis 
of PD (Gu et al. 2015). It has been reported that melatonin 
affects clock gene expression. Torres-Farfan et al.(Torres-
Farfan et al. 2006) found that maternal melatonin affects 
clock genes such as BMAL1 and Per in primate fetus. Mela-
tonin regulates different clock genes such as mPer1, mCry1, 
and BMAL1 via MT1 receptor (von Gall et al. 2005). In a 
study, administration of melatonin led to the restoration of 
rPer1 daily rhythm in PD (Mattam and Jagota 2015).
The biological effects of melatonin are extremely wide-
spread. Melatonin could control molecular action such as 
oxidative stress signaling (Galano et al. 2011; Reiter et al. 
2000), inflammatory pathways (Li et al. 2005; Kim et al. 
2012), immune responses (Moore and Siopes 2000; Car-
rillo-Vico et al. 2006), apoptosis (Mayo et al. 1998; Muñoz-
Casares et al. 2006), physiological rhythm (Zawilska et al. 
2009; Skene and Arendt 2006) as well as influencing chronic 
diseases, such as, diabetes (Winiarska et al. 2006; Espino 
et al. 2011), obesity (Agil et al. 2011; Hussein et al. 2007), 
kidney injuries (Hussein et al. 2007; Leibowitz et al. 2016), 
cardiovascular diseases (Dominguez-Rodriguez 2012; 
Dominguez-Rodriguez et al. 2012), cancers (Tamtaji et al. 
2019b), neurological disorders (Wang and Wang 2006; Yang 
et al. 2011; Farez et al. 2015) and aging-related conditions 
(Karasek and Reiter 2002; Wu and Swaab 2005). Circulat-
ing melatonin levels are reduced in patients with PD (Breen 
et al. 2014). Decreased melatonin levels markedly are cor-
related with disease severity and hypothalamic gray matter 
volume in patients with PD (Breen et al. 2016). Melatonin 
decreased the degenerating neurons, oxidative stress, and 
apoptosis in paraquat and maneb-induced PD in mice (Sin-
ghal et al. 2011). In addition, a study reported that melatonin 
led to formation of scavenged ·OH, increased GSH, and 
increase in the activity of cytosolic SOD in neuronal peri-
karya of PD mice (Thomas and Mohanakumar 2004). Also, 
this supplement prevented upregulation of CDK5 in the 
striatum and decreased a-synuclein aggregation in animal 
model of PD (Su et al. 2015). Kunz and Mahlberg (2010) 
noted that melatonin improved sleep behavior in patients 
with PD. The aim of this review is to assess the current 
knowledge related to the effects of melatonin supplementa-
tion on PD and its pathophysiology.
The Effects of Melatonin on Clinical 
Symptom in Patients with PD
Rare studies evaluated the effects of melatonin on patients 
with PD. A study reported that administration of melatonin 
improved nonmotor disorders in patients with PD (Dowl-
ing et al. 2005). Kunz et al. (2010) noted that melatonin 
improved sleep behavior in patients with PD. Many stud-
ies have shown that melatonin supplementation improves 
the quality of sleep. However, motor symptoms were not 
improved in PD patients (Medeiros et al. 2007). There are 
no studies on the effects of melatonin supplementation on 
molecular mechanism in PD patients. More studies clearly 
need to evaluate the effects of melatonin on clinical symp-
toms and molecular mechanisms in clinical studies.
The Effects of Melatonin on Molecular 
Mechanisms in the In Vitro and In Vivo 
Model of PD
Melatonin and Oxidative Stress in PD
Oxidative stress is involved in neurodegeneration in PD and 
activation of c-Jun N-terminal kinase (JNK) and c-Jun that 
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are important role in cell death (Jenner 2003; Wang et al. 
2008). Few studies reported the effects of melatonin on oxi-
dative stress signaling in PD. Administration of melatonin 
(20 and 30 mg/kg) increased superoxide dismutase (SOD), 
mitochondrial complex-I activity, and glutathione (GSH) in 
SN in a rat model of PD induced by homocysteine. In addi-
tion, melatonin at dosage of 10, 20 and 30 mg/kg decreased 
hydroxyl radical (·OH) and increased catalase in the SN 
of rat model of PD induced by homocysteine (Paul et al. 
2018). In a study, melatonin 10 mg/kg was administered, 
and this led to increases of GSSG/GSH ratio and increased 
GSH in some part of brain in rat model of PD induced by 
MPP+ (Chen et al. 2002). Melatonin also decreased 8-Oxo-
guanine in rat model of PD induced by MPTP (Chen et al. 
2005). Jin et al. (1998) reported that melatonin decreased 
MDA in rat model of PD induced by MPTP. In addition, 
melatonin decreased MDA, increased SOD, decreased 
dopaminergic neuron death, increased CAT, and increased 
GPx in the SN of rat model of PD induced by 6-OHDA 
(Ozsoy et al. 2015). Melatonin increased GSH and CAT 
in SN, increased GSH in the striatum and increased SOD 
contents in the SN in rat model of PD induced by rotenone 
(Saravanan et al. 2007). Melatonin decreased the number 
of degenerating neurons and lipid peroxidation in the para-
quat and maneb-induced PD in mice (Singhal et al. 2011). 
Thomas and Mohanakumar (2004) reported that melatonin 
led to scavenged ·OH formed, increased GSH, increase in 
the activity of cytosolic SOD in neuronal perikarya of PD 
mice. In addition, a study reported that melatonin signifi-
cantly decreased oxidative stress in in vitro model of PD 
induced by MPP (+) (Chuang et al. 2016). Another study 
also indicated that administration of melatonin significantly 
decreased oxidative stress caused by MPTP-induced PD in 
mice (Ortiz et al. 2013).
Melatonin and Apoptosis Pathways in PD
Increased oxidative stress, decreased antioxidant enzymes, 
and mitochondrial dysfunction lead to apoptosis and cell 
death of neurons (Annunziato et al. 2003; Jenner 2003). 
Some animal models of PD are induced using 6-hydroxy-
dopamine (6-OHDA) (Simola et al. 2007; Thiele et al. 
2012), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) (Meredith and Rademacher 2011; Jackson-
Lewis and Przedborski 2007), homocysteine (Mansouri 
et  al. 2012), and rotenone (Sherer et  al. 2003; Tanner 
et al. 2011). 6-OHDA causes cell apoptosis in both in vivo 
(Zuch et al. 2000) and in vitro (Blum et al. 1997). The 
different proteins such as p38 MAPK, Bax, and caspases 
are activated in apoptotic cascade by 6-OHDA (Mei and 
Niu 2014; Cheng et al. 2007; Gomez-Lazaro et al. 2008; 
Ochu et  al. 1998). 6-OHDA downregulates Bcl-2 and 
Bcl-w gene expressions and upregulates Bax and Bad 
expressions. However, Glial cell line derived neurotrophic 
factor (GDNF) is reversed these changes (Cao et al. 2013). 
Caspase-3 activation is associated to MPTP-induced PD 
in rodents (Yamada et al. 2010). MPTP activate caspase-9 
via cytochrome c release that leads to activation of cas-
pase-8 and Bid cleavage which trigger to dopaminergic 
cell death (Viswanath et al. 2001). MPTP neurotoxicity 
leads to dopaminergic cell death via activation of the cas-
pase-11 cascade and inflammatory cascade, in addition 
to mitochondrial apoptotic process (Furuya et al. 2004). 
MPTP/MPP+ also leads to the activation and phosphoryla-
tion of JNK, JNK kinase (MKK4), and c-Jun (Xia et al. 
2001). Rotenone induces the activation of caspase-3 which 
leads to dopaminergic cell death (Ahmadi et al. 2003). 
Increased caspase-3, caspase-9, and Hsp60 are observed 
in the rotenone-induced PD model (Angeline et al. 2012).
Few studies reported the effects of melatonin on cell 
death and apoptosis signaling in PD. Melatonin (10 mg/kg) 
decreased DNA fragmentation in striatum and midbrain, 
lowered apoptosis cells in midbrain in PD rats induced by 
MPTP (Acuna-Castroviejo et al. 1997). Administration of 
melatonin (500 μg/kg, i.p) limited DNA fragmentation in PD 
rats induced by MPTP (Antolin et al. 2002). In a study, mel-
atonin 10 mg/kg was administered, and this led to decreased 
apoptosis cell in the striatum in rat model of PD induced by 
MPP + (Chen et al. 2002). Patki and Lau (2011) reported 
that melatonin improved mitochondrial deficit in mice model 
of PD induced by MPTP. Melatonin decreased P-p53, Bax, 
and caspase 9 expressions and increased the levels of p53 in 
the paraquat- and maneb-induced PD in mice (Singhal et al. 
2011) In addition, melatonin decreased caspase-3 and dopa-
minergic neuron death, and increased expression of Bcl-2 in 
PD rats (Yildirim et al. 2014). In addition, a study reported 
that melatonin significantly decreased neuron death and 
mitochondrial fragmentation in vitro model of PD induced 
by MPP (+) (Chuang et al. 2016). Moreover, melatonin has 
neuroprotective effects through inhibition of calpain/cdk5 
signaling in in vitro model of PD (Alvira et al. 2006).
Melatonin and Autophagy Pathway in PD
Autophagy has an essential role the pathogenesis of PD 
(Lynch-Day et al. 2012). MPTP as an inductor of PD leads 
to increase in CDK5 in MPTP-induced PD in mice. CDK5 
is involved in the regulation of autophagy to mediation of 
neuronal cell death and neurotoxicity (Naskar et al. 2015b). 
However, melatonin decreased kainic acid-induced neuro-
toxicity through inhibition of autophagy (Chang et al. 2012). 
Another study also reported that melatonin improved CDK5-
induced autophagy and cell death in PD induced by MPTP in 
monkey (Su et al. 2015). More studies are required to evalu-
ate the effects of melatonin on autophagy pathways in PD.
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Melatonin and Neuroinflammation in PD
Cyclooxygenase type-2 (COX-2) is involved in neuroin-
flammation in PD (Choi et al. 2009). Moreover, it has been 
reported that MPTP elevated Inducible nitric oxide synthase 
(iNOS) activity in striatum and substantia nigra. In addi-
tion, iNOS-dependent increased nitric oxide was seen that 
is known as a pathological hallmark of neuroinflammation 
in PD (López et al. 2017). However, melatonin prevented 
elevation of iNOS in MPTP-induced PD mice (López et al. 
2017). In addition, administration of melatonin signifi-
cantly decreased COX-2 activity in MPTP-induced PD in 
mice (Ortiz et al. 2013). Rare studies evaluated the effects 
of melatonin on neuroinflammation in PD. More studies are 
required to evaluating the effects of melatonin on neuroin-
flammation in PD.
Melatonin and Pathological Hallmarks
The overexpression of α-synuclein has an important role in 
the pathogenesis of PD (Eller and Williams 2011; Zarranz 
et  al. 2004). α-Synuclein induces dopaminergic nerve 
terminal degeneration (Saha et  al. 2000; Masliah et  al. 
2000). Aggregation of non β amyloid component (NAC) 
and α-synuclein proteins induced neuronal apoptosis (El-
Agnaf et al. 1998; Lee et al. 2001). α-Synuclein induces 
apoptosis through the activation of caspases, while Hsp70 
inhibits these processes as by sequestering and binding to 
α-synuclein (Flower et al. 2005).
Studies that evaluated the effects of melatonin on 
α-synuclein in PD are rare. Melatonin at a dosage of 10 mg/
kg decreased alpha-synuclein in striatum in rat model of 
PD induced by rotenone (Lin et al. 2008). Also, this supple-
ment prevented upregulation of CDK5 in the striatum and 
decreased a-synuclein aggregation in PD induced by MPTP 
in monkey (Su et al. 2015). In addition, a study reported that 
α-synuclein triggers impairment of respiration in yeast; how-
ever, melatonin improved this condition (Zampol and Barros 
2018). More studies are required to evaluate the effects of 
melatonin on α-synuclein in PD.
Melatonin and Neurotransmitters
Decreases in dopamine levels and dopaminergic neurons are 
induced in PD (Berendse et al. 2001). Few studies evaluated 
the effects of melatonin on dopamine in PD. Patki and Lau 
(2011) reported that melatonin increased nigral and striatal 
dopamine concentrations and improved locomotor deficit 
and mitochondrial deficit in mice model of PD induced by 
MPTP. Another study indicated that striatal dopamine loss 
induced by MPTP was not improved by melatonin in MPTP-
induced PD in mice. However, low doses of L-DOPA along 
with melatonin significantly decreased striatal dopamine loss 
and improved in both akinesia and catalepsy MPTP-induced 
PD in mice (Naskar et al. 2013). A study by Brito-Armas 
et al. (2013) reported that melatonin prevented dopaminergic 
cell loss caused by mutant alpha-synuclein.
Daily rhythms related to serotonin metabolism and gene 
expression of various clock genes in the animal model of PD 
induced by rotenone. Decreases in mean 24-h levels of mela-
tonin, 5-hydroxytryptophan, serotonin, and N-acetyl seroto-
nin and in the suprachiasmatic nucleus of animal model of 
PD induced by rotenone in rats could be due to reduction of 
activity of tryptophan hydroxylase. However, administration 
of melatonin restored these changes (Naskar et al. 2015b). 
More studies are required to evaluate the effects of melatonin 
on dopamine and other neurotransmitters in PD.
Genetical Changes
Mutations of leucine-rich repeat kinase2 (LRRK2) gene have 
important role in pathogenesis of PD (Gilks et al. 2005), 
whish mutations of LRRK2 leads to cell death and neuro-
degeneration (Iaccarino et al. 2007). A study reported that 
melatonin decreased hLRRK2-induced memory dysfunc-
tion in the drosophila model of PD (Ran et al. 2018). In 
addition, a study indicated that hLRRK2 is involved in the 
synaptic dysfunction and sleep disorder in PD, while mela-
tonin decreased hLRRK2-induced synaptic dysfunction and 
sleep disorders (Sun et al. 2016). Moreover, administration 
of melatonin led to rescue of zebrafish embryos from the 
MPTP-induced PD phenotype restoring the parkin/PINK1/
DJ-1/MUL1 (Díaz-Casado et al. 2016).
Melatonin, an Ideal Adjuvant to Treatment 
with L‑DOPA
It is an interesting point to note that the combination of 
melatonin with L-DOPA was more effective than mono-
therapy. A study indicated that combination of melatonin 
with L-DOPA had more neuroprotective effects in animal 
model of PD (Naskar et al. 2013). Melatonin increased 
treatment effects of L-DOPA, and decreased its dosage in 
animal model of PD (Naskar et al. 2015a). Therefore, mela-
tonin may be a perfect and ideal adjuvant to treatment with 
L-DOPA in PD.
Conclusions
Increasing evidence documents that melatonin has a pro-
found influence on PD. Herein we summarized the effects of 
melatonin on apoptosis, autophagy, oxidative stress, inflam-
mation, α-synuclein aggregation, and changes in the neuro-
transmitters in preclinical and clinical investigations related 
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to PD. Administration of melatonin led to inhibition of some 
pathways related to apoptosis, autophagy, oxidative stress, 
inflammation, α-synuclein aggregation, and dopamine loss 
in PD (Fig. 1). In addition, melatonin improved some non-
motor symptoms in patients with PD. Further assessments 
on the impacts of melatonin on PD-related pathways at the 
molecular level and clinical symptoms are required. Moreo-
ver, preclinical studies documented that melatonin may be a 
perfect and ideal adjuvant for treatment with L-DOPA in PD, 
to confirm which finding more clinical studies are needed.
Author Contributions O-RT, RJ-R, RA, ED, EK, and ZA contributed in 
the conception and design of the work and drafting of the manuscript. 
All authors confirmed the final version for submission.
Funding No specific source of funding is associated with this work.
Compliance with Ethical Standards 
Conflict of interest The authors declare there are no conflicts of inter-
est.
References
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, 
Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L 
(2010) Mild cognitive impairment in Parkinson disease: a mul-
ticenter pooled analysis. Neurology 75(12):1062–1069
Acuna-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter 
RJ (1997) Melatonin is protective against MPTP-induced striatal 
and hippocampal lesions. Life Sci 60(2):Pl23–Pl29
Agil A, Navarro-Alarcón M, Ruiz R, Abuhamadah S, El-Mir MY, 
Vázquez GF (2011) Beneficial effects of melatonin on obesity 
and lipid profile in young Zucker diabetic fatty rats. J Pineal Res 
50(2):207–212
Ahmadi FA, Linseman DA, Grammatopoulos TN, Jones SM, 
Bouchard RJ, Freed CR, Heidenreich KA, Zawada WM (2003) 
The pesticide rotenone induces caspase-3-mediated apoptosis 
in ventral mesencephalic dopaminergic neurons. J Neurochem 
87(4):914–921
Alvira D, Tajes M, Verdaguer E, Acuña-Castroviejo D, Folch J, 
Camins A, Pallas M (2006) Inhibition of the cdk5/p25 fragment 
formation may explain the antiapoptotic effects of melatonin 
in an experimental model of Parkinson’s disease. J Pineal Res 
40(3):251–258
Angeline MS, Chaterjee P, Anand K, Ambasta R, Kumar P (2012) 
Rotenone-induced parkinsonism elicits behavioral impairments 
Fig. 1  Schematic representation of targeting molecular signaling pathway by melatonin in the PD
 Cellular and Molecular Neurobiology
1 3
and differential expression of parkin, heat shock proteins and 
caspases in the rat. Neuroscience 220:291–301
Anglade P, Vyas S, Javoy-Agid F, Herrero M, Michel P, Marquez J, 
Mouatt-Prigent A, Ruberg M, Hirsch E, Agid Y (1997) Apopto-
sis and autophagy in nigral neurons of patients with Parkinson’s 
disease. Histol Histopathol 12(1):25–32
Annunziato L, Amoroso S, Pannaccione A, Cataldi M, Pignataro G, 
D’Alessio A, Sirabella R, Secondo A, Sibaud L, Di Renzo G 
(2003) Apoptosis induced in neuronal cells by oxidative stress: 
role played by caspases and intracellular calcium ions. Toxicol 
Lett 139(2–3):125–133
Antolin I, Mayo JC, Sainz RM, del Brio Mde L, Herrera F, Mar-
tin V, Rodriguez C (2002) Protective effect of melatonin in a 
chronic experimental model of Parkinson’s disease. Brain Res 
943(2):163–173
Balash Y, Korczyn AD, Migirov AA, Gurevich T (2019) Quality of life 
in Parkinson’s disease: a gender specific perspective. Acta Neurol 
Scand. https ://doi.org/10.1111/ane.13095 
Beker-Acay M, Turamanlar O, Horata E, Unlu E, Fidan N, Oruc S 
(2016) Assessment of pineal gland volume and calcification 
in healthy subjects: is it related to aging? J Belg Soc Radiol 
100(1):13
Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof 
JC, Wolters EC (2001) Subclinical dopaminergic dysfunction 
in asymptomatic Parkinson’s disease patients’ relatives with a 
decreased sense of smell. Ann Neurol 50(1):34–41
Blum D, Wu Y, Nissou M-F, Arnaud S, Benabid A-L, Verna J-M 
(1997) p53 and Bax activation in 6-hydroxydopamine-induced 
apoptosis in PC12 cells. Brain Res 751(1):139–142
Borzabadi S, Oryan S, Eidi A, Aghadavod E, Kakhaki RD, Tamtaji 
OR, Taghizadeh M, Asemi Z (2018) The effects of probiotic 
supplementation on gene expression related to inflammation, 
insulin and lipid in patients with Parkinson’s disease: a rand-
omized, double-blind, placebo-controlled trial. Arch Iran Med 
(AIM) 21(7):289
Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy 
AB, Barker RA (2014) Sleep and circadian rhythm regulation in 
early Parkinson disease. JAMA Neurol 71(5):589–595. https ://
doi.org/10.1001/jaman eurol .2014.65
Breen DP, Nombela C, Vuono R, Jones PS, Fisher K, Burn DJ, Brooks 
DJ, Reddy AB, Rowe JB, Barker RA (2016) Hypothalamic vol-
ume loss is associated with reduced melatonin output in Par-
kinson’s disease. Mov Disord 31(7):1062–1066. https ://doi.
org/10.1002/mds.26592 
Brito-Armas J, Baekelandt V, Castro-Hernández J, González-Hernán-
dez T, Rodríguez M, Castro R (2013) Melatonin prevents dopa-
minergic cell loss induced by lentiviral vectors expressing A30P 
mutant alpha-synuclein. Histol Histopathol 28(8):999–1006
Bumb JM, Schilling C, Enning F, Haddad L, Paul F, Lederbogen F, 
Deuschle M, Schredl M, Nolte I (2014) Pineal gland volume in 
primary insomnia and healthy controls: a magnetic resonance 
imaging study. J Sleep Res 23(3):276–282
Cai Y, Liu S, Sothern R, Xu S, Chan P (2010) Expression of clock 
genes Per1 and Bmal1 in total leukocytes in health and Parkin-
son’s disease. Eur J Neurol 17(4):550–554
Cao JP, Niu HY, Wang HJ, Huang XG, Gao DS (2013) NF-κB p65/
p52 plays a role in GDNF up-regulating Bcl-2 and Bcl-w expres-
sion in 6-OHDA-induced apoptosis of MN9D cell. Int J Neurosci 
123(10):705–710
Carrillo-Vico A, Reiter RJ, Lardone PJ, Herrera JL, Fernández-Mon-
tesinos R, Guerrero JM, Pozo D (2006) The modulatory role of 
melatonin on immune responsiveness. Curr Opin Investig Drugs 
7(5):423
Chang CF, Huang HJ, Lee HC, Hung KC, Wu RT, Lin AMY (2012) 
Melatonin attenuates kainic acid-induced neurotoxicity in mouse 
hippocampus via inhibition of autophagy and α-synuclein aggre-
gation. J Pineal Res 52(3):312–321
Chen ST, Chuang JI, Hong MH, Eric I, Li C (2002) Melatonin attenu-
ates MPP+-induced neurodegeneration and glutathione impair-
ment in the nigrostriatal dopaminergic pathway. J Pineal Res 
32(4):262–269
Chen LJ, Gao YQ, Li XJ, Shen DH, Sun FY (2005) Melatonin protects 
against MPTP/MPP+-induced mitochondrial DNA oxidative 
damage in vivo and in vitro. J Pineal Res 39(1):34–42
Cheng B, Yang X, Hou Z, Lin X, Meng H, Li Z, Liu S (2007) D-β-
hydroxybutyrate inhibits the apoptosis of PC12 cells induced 
by 6-OHDA in relation to up-regulating the ratio of Bcl-2/Bax 
mRNA. Auton Neurosci 134(1–2):38–44
Choi S-H, Aid S, Bosetti F (2009) The distinct roles of cyclooxyge-
nase-1 and-2 in neuroinflammation: implications for translational 
research. Trends Pharmacol Sci 30(4):174–181
Chuang JI, Pan IL, Hsieh CY, Huang CY, Chen PC, Shin JW (2016) 
Melatonin prevents the dynamin-related protein 1-dependent 
mitochondrial fission and oxidative insult in the cortical neu-
rons after 1-methyl-4-phenylpyridinium treatment. J Pineal Res 
61(2):230–240
Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross 
CA, Dawson VL, Dawson TM (2001) Parkin ubiquitinates the 
α-synuclein–interacting protein, synphilin-1: implications for 
Lewy-body formation in Parkinson disease. Nat Med 7(10):1144
Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson 
disease: a review. JAMA 311(16):1670–1683
Delucca BJ, Richardson RM, Stewart JT (2018) Melatonin treatment 
of visual hallucinations in Parkinson disease. J Clin Psychophar-
macol 38(5):532–534
Díaz-Casado ME, Lima E, García JA, Doerrier C, Aranda P, Sayed RK, 
Guerra-Librero A, Escames G, López LC, Acuña-Castroviejo 
D (2016) Melatonin rescues zebrafish embryos from the par-
kinsonian phenotype restoring the parkin/PINK 1/DJ-1/MUL 1 
network. J Pineal Res 61(1):96–107
Dominguez-Rodriguez A (2012) Melatonin in cardiovascular disease. 
Taylor & Francis, Routledge
Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ (2012) Mela-
tonin and cardiovascular disease: myth or reality? Rev Esp Car-
diol 65(03):215–218
Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ 
(2005) Melatonin for sleep disturbances in Parkinson’s disease. 
Sleep Med 6(5):459–466
Dubocovich ML, Markowska M (2005) Functional MT 1 and MT 2 
melatonin receptors in mammals. Endocrine 27(2):101–110
El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi 
E, Pessi A, Neill D, Wallace A (1998) Aggregates from mutant 
and wild-type α-synuclein proteins and NAC peptide induce 
apoptotic cell death in human neuroblastoma cells by formation 
of β-sheet and amyloid-like filaments. FEBS Lett 440(1–2):71–75
Eller M, Williams DR (2011) α-Synuclein in Parkinson disease 
and other neurodegenerative disorders. Clin Chem Lab Med 
49(3):403–408
Espino J, Pariente JA, Rodríguez AB (2011) Role of melatonin on 
diabetes-related metabolic disorders. World J Diabetes 2(6):82
Farez MF, Mascanfroni ID, Méndez-Huergo SP, Yeste A, Murugaiyan 
G, Garo LP, Aguirre MEB, Patel B, Ysrraelit MC, Zhu C (2015) 
Melatonin contributes to the seasonality of multiple sclerosis 
relapses. Cell 162(6):1338–1352
Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN (2005) 
Heat shock prevents alpha-synuclein-induced apoptosis in a yeast 
model of Parkinson’s disease. J Mol Biol 351(5):1081–1100
Furuya T, Hayakawa H, Yamada M, Yoshimi K, Hisahara S, Miura M, 
Mizuno Y, Mochizuki H (2004) Caspase-11 mediates inflam-
matory dopaminergic cell death in the 1-methyl-4-phenyl-1, 2, 
Cellular and Molecular Neurobiology 
1 3
3, 6-tetrahydropyridine mouse model of Parkinson’s disease. J 
Neurosci 24(8):1865–1872
Galano A, Tan DX, Reiter RJ (2011) Melatonin as a natural ally against 
oxidative stress: a physicochemical examination. J Pineal Res 
51(1):1–16
Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, 
Shaw K, Bhatia KP, Bonifati V, Quinn NP (2005) A common 
LRRK2 mutation in idiopathic Parkinson’s disease. The Lancet 
365(9457):415–416
Gomez-Lazaro M, Galindo MF, Concannon CG, Segura MF, Fernan-
dez-Gomez FJ, Llecha N, Comella JX, Prehn JH, Jordan J (2008) 
6-Hydroxydopamine activates the mitochondrial apoptosis path-
way through p38 MAPK-mediated, p53-independent activation 
of Bax and PUMA. J Neurochem 104(6):1599–1612
Grosshans M, Vollmert C, Vollstaedt-Klein S, Nolte I, Schwarz E, 
Wagner X, Leweke M, Mutschler J, Kiefer F, Malte Bumb J 
(2016) The association of pineal gland volume and body mass 
in obese and normal weight individuals: a pilot study. Psychiatri 
Danub 28(3):220–224
Gu Z, Wang B, Zhang Y-B, Ding H, Zhang Y, Yu J, Gu M, Chan 
P, Cai Y (2015) Association of ARNTL and PER1 genes with 
Parkinson’s disease: a case-control study of Han Chinese. Sci 
Rep 5:15891
Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko 
R, Hara M, Suzuki T, Reiter RJ (1995) Identification of mela-
tonin in plants and its effects on plasma melatonin levels and 
binding to melatonin receptors in vertebrates. Biochem Mol Biol 
Int 35(3):627–634
Hill SM, Cheng C, Yuan L, Mao L, Jockers R, Dauchy B, Blask DE 
(2013) Age-related decline in melatonin and its MT1 receptor are 
associated with decreased sensitivity to melatonin and enhanced 
mammary tumor growth. Curr Aging Sci 6(1):125–133
Hughes A, Daniel S, Kilford L, Lees A (1992) Accuracy of clinical 
diagnosis of idiopathic Parkinson’s disease: a clinicopathological 
study of 100 cases. Neurol Neurosurg Psychiatry 55(3):181–184
Hussein MR, Ahmed OG, Hassan AF, Ahmed MA (2007) Intake 
of melatonin is associated with amelioration of physiological 
changes, both metabolic and morphological pathologies associ-
ated with obesity: an animal model. Int J Exp Pathol 88(1):19–29
Iaccarino C, Crosio C, Vitale C, Sanna G, Carrì MT, Barone P (2007) 
Apoptotic mechanisms in mutant LRRK2-mediated cell death. 
Hum Mol Genet 16(11):1319–1326
Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse 
model of Parkinson’s disease. Nat Protoc 2(1):141
Jankovic J, Stacy M (2007) Medical management of levodopa-associ-
ated motor complications in patients with Parkinson’s disease. 
CNS Drugs 21(8):677–692
Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 
53(S3):S26–S38
Jin BK, Shin DY, Jeong MY, Gwag MR, Baik HW, Yoon KS, Cho YH, 
Joo WS, Kim YS, Baik HH (1998) Melatonin protects nigral 
dopaminergic neurons from 1-methyl-4-phenylpyridinium 
(MPP +) neurotoxicity in rats. Neurosci Lett 245(2):61–64
Kalf JG, Borm GF, de Swart BJ, Bloem BR, Zwarts MJ, Munneke M 
(2011) Reproducibility and validity of patient-rated assessment 
of speech, swallowing, and saliva control in Parkinson’s disease. 
Arch Phys Med Rehabil 92(7):1152–1158
Karasek M, Reiter R (2002) Melatonin and aging. Neuro Endocrinol 
Lett 23:14–16
Kim J-Y, Lee Y-D, Kim B-J, Kim S-P, Kim D-H, Jo K-J, Lee S-K, 
Lee K-H, Baik H-W (2012) Melatonin improves inflammatory 
cytokine profiles in lung inflammation associated with sleep dep-
rivation. Mol Med Rep 5(5):1281–1284
Kunz D, Mahlberg R (2010) A two-part, double-blind, placebo-con-
trolled trial of exogenous melatonin in REM sleep behaviour 
disorder. J Sleep Res 19(4):591–596
Kunz D, Schmitz S, Mahlberg R, Mohr A, Stoter C, Wolf KJ, Herrmann 
WM (1999) A new concept for melatonin deficit: on pineal cal-
cification and melatonin excretion. Neuropsychopharmacology 
21(6):765–772. https ://doi.org/10.1016/s0893 -133x(99)00069 -x
Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and 
functional coupling of α-synuclein to the dopamine transporters 
accelerate dopamine-induced apoptosis. FASEB J 15(6):916–926
Leibowitz A, Volkov A, Voloshin K, Shemesh C, Barshack I, Gross-
man E (2016) Melatonin prevents kidney injury in a high salt 
diet-induced hypertension model by decreasing oxidative stress. 
J Pineal Res 60(1):48–54
Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W (1958) Isolation 
of melatonin, the pineal gland factor that lightens melanocyteS1. 
J Am Chem Soc 80(10):2587
Li J-H, Yu J-P, Yu H-G, Xu X-M, Yu L-L, Liu J, Luo H-S (2005) Mel-
atonin reduces inflammatory injury through inhibiting NF-κB 
activation in rats with colitis. Mediat Inflamm 4:185–193
Lima LA, Lopes MJP, Costa RO, Lima FAV, Neves KRT, Calou IB, 
Andrade GM, Viana GS (2018) Vitamin D protects dopaminergic 
neurons against neuroinflammation and oxidative stress in hemi-
parkinsonian rats. J Neuroinflammation 15(1):249
Lin CH, Huang JY, Ching CH, Chuang JI (2008) Melatonin reduces 
the neuronal loss, downregulation of dopamine transporter, and 
upregulation of D2 receptor in rotenone-induced parkinsonian 
rats. J Pineal Res 44(2):205–213. https ://doi.org/10.1111/j.1600-
079X.2007.00510 .x
López A, Ortiz F, Doerrier C, Venegas C, Fernández-Ortiz M, Aranda 
P, Díaz-Casado ME, Fernández-Gil B, Barriocanal-Casado E, 
Escames G (2017) Mitochondrial impairment and melatonin 
protection in parkinsonian mice do not depend of inducible or 
neuronal nitric oxide synthases. PLoS ONE 12(8):e0183090
Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ (2012) The 
role of autophagy in Parkinson’s disease. Cold Spring Harb Per-
spect Med 2:a009357
Mahboubi M, Taghizadeh M, Talaei SA, Firozeh SMT, Rashidi AA, 
Tamtaji OR (2016) Combined administration of Melissa offici-
nalis and Boswellia serrata extracts in an animal model of mem-
ory. Iran J Psychiatry Behav Sci 10(3):e681
Mansouri Z, Sabetkasaei M, Moradi F, Masoudnia F, Ataie A (2012) 
Curcumin has neuroprotection effect on homocysteine rat model 
of Parkinson. J Mol Neurosci 47(2):234–242
Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, 
Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss 
and inclusion body formation in α-synuclein mice: implications 
for neurodegenerative disorders. Science 287(5456):1265–1269
Mattam U, Jagota A (2015) Daily rhythms of serotonin metabolism 
and the expression of clock genes in suprachiasmatic nucleus 
of rotenone-induced Parkinson’s disease male Wistar rat 
model and effect of melatonin administration. Biogerontology 
16(1):109–123
Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriguez C 
(1998) Melatonin prevents apoptosis induced by 6-hydroxydo-
pamine in neuronal cells: implications for Parkinson’s disease. J 
Pineal Res 24(3):179–192
Medeiros CAM, De Bruin PFC, Lopes LA, Magalhães MC, de Lourdes 
Seabra M, de Bruin VMS (2007) Effect of exogenous melatonin 
on sleep and motor dysfunction in Parkinson’s disease. J Neurol 
254(4):459–464
Mei J-m, Niu C-s (2014) Effects of CDNF on 6-OHDA-induced apop-
tosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 
activation. Neurol Sci 35(8):1275–1280
Mercolini L, Mandrioli R, Raggi MA (2012) Content of melatonin and 
other antioxidants in grape-related foodstuffs: measurement using 
a MEPS-HPLC-F method. J Pineal Res 53(1):21–28
Meredith GE, Rademacher DJ (2011) MPTP mouse models of Parkin-
son’s disease: an update. J Parkinson’s Dis 1(1):19–33
 Cellular and Molecular Neurobiology
1 3
Moore C, Siopes T (2000) Effects of lighting conditions and melatonin 
supplementation on the cellular and humoral immune responses 
in Japanese quail Coturnix coturnix japonica. Gen Comp Endo-
crinol 119(1):95–104
Muñoz-Casares FC, Padillo FJ, Briceño J, Collado JA, Muñoz-
Castañeda JR, Ortega R, Cruz A, Túnez I, Montilla P, Pera 
C (2006) Melatonin reduces apoptosis and necrosis induced 
by ischemia/reperfusion injury of the pancreas. J Pineal Res 
40(3):195–203
Naskar A, Manivasagam T, Chakraborty J, Singh R, Thomas B, Dha-
nasekaran M, Mohanakumar KP (2013) Melatonin synergizes 
with low doses of L-DOPA to improve dendritic spine density 
in the mouse striatum in experimental Parkinsonism. J Pineal 
Res 55(3):304–312
Naskar A, Prabhakar V, Singh R, Dutta D, Mohanakumar KP (2015a) 
Melatonin enhances L-DOPA therapeutic effects, helps to reduce 
its dose, and protects dopaminergic neurons in 1-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. 
J Pineal Res 58(3):262–274. https ://doi.org/10.1111/jpi.12212 
Naskar A, Prabhakar V, Singh R, Dutta D, Mohanakumar KP (2015b) 
Melatonin enhances L-DOPA therapeutic effects, helps to reduce 
its dose, and protects dopaminergic neurons in 1-methyl-4-phe-
nyl-1, 2, 3, 6-tetrahydropyridine-induced parkinsonism in mice. 
J Pineal Res 58(3):262–274
Ochu EE, Rothwell NJ, Waters CM (1998) Caspases mediate 
6-hydroxydopamine-induced apoptosis but not necrosis in PC12 
cells. J Neurochem 70(6):2637–2640
Ortiz GG, Pacheco-Moisés FP, Gómez-Rodríguez VM, González-Ren-
ovato ED, Torres-Sánchez ED, Ramírez-Anguiano AC (2013) 
Fish oil, melatonin and vitamin E attenuates midbrain cyclooxy-
genase-2 activity and oxidative stress after the administration 
of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Metab Brain 
Dis 28(4):705–709
Ozsoy O, Yildirim FB, Ogut E, Kaya Y, Tanriover G, Parlak H, Agar A, 
Aslan M (2015) Melatonin is protective against 6-hydroxydopa-
mine-induced oxidative stress in a hemiparkinsonian rat model. 
Free Radic Res 49(8):1004–1014. https ://doi.org/10.3109/10715 
762.2015.10271 98
Pacelli C, Rotundo G, Lecce L, Menga M, Bidollari E, Scrima R, 
Cela O, Piccoli C, Cocco T, Vescovi AL (2019) Parkin mutation 
affects clock gene-dependent energy metabolism. Int J Mol Sci 
20(11):2772
Paltsev MA, Polyakova VO, Kvetnoy IM, Anderson G, Kvetnaia TV, 
Linkova NS, Paltseva EM, Rubino R, De Cosmo S, De Cata A, 
Mazzoccoli G (2016) Morphofunctional and signaling molecules 
overlap of the pineal gland and thymus: role and significance in 
aging. Oncotarget 7(11):11972–11983. https ://doi.org/10.18632 
/oncot arget .7863
Patki G, Lau YS (2011) Melatonin protects against neurobehavioral and 
mitochondrial deficits in a chronic mouse model of Parkinson’s 
disease. Pharmacol Biochem Behav 99(4):704–711. https ://doi.
org/10.1016/j.pbb.2011.06.026
Paul R, Phukan BC, Justin Thenmozhi A, Manivasagam T, Bhattacha-
rya P, Borah A (2018) Melatonin protects against behavioral 
deficits, dopamine loss and oxidative stress in homocysteine 
model of Parkinson’s disease. Life Sci 192:238–245. https ://doi.
org/10.1016/j.lfs.2017.11.016
Perez-Lloret S, Nègre-Pagès L, Ojero-Senard A, Damier P, Destée A, 
Tison F, Merello M, Rascol O, Group CS (2012) Oro-buccal 
symptoms (dysphagia, dysarthria, and sialorrhea) in patients 
with Parkinson’s disease: preliminary analysis from the French 
COPARK cohort. Eur J Neurol 19(1):28–37
Ran D, Xie B, Gan Z, Sun X, Gu H, Yang J (2018) Melatonin attenu-
ates hLRRK2-induced long-term memory deficit in a Drosophila 
model of Parkinson’s disease. Biomed Rep 9(3):221–226
Reiter RJ, Tan D-x, Osuna C, Gitto E (2000) Actions of melatonin in 
the reduction of oxidative stress. J Biomed Sci 7(6):444–458
Reiter RJ, Tan DX, Burkhardt S, Manchester LC (2001) Melatonin in 
plants. Nutr Rev 59(9):286–290
Reppert SM (1997) Melatonin receptors: molecular biology of a 
new family of G protein-coupled receptors. J Biol Rhythms 
12(6):528–531
Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buch-
man VL (2000) Induction of neuronal death by α-synuclein. Eur 
J Neurosci 12(8):3073–3077
Saravanan KS, Sindhu KM, Mohanakumar KP (2007) Melatonin 
protects against rotenone-induced oxidative stress in a hemipa-
rkinsonian rat model. J Pineal Res 42(3):247–253. https ://doi.
org/10.1111/j.1600-079X.2006.00412 .x
Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, 
Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT (2003) 
Mechanism of toxicity in rotenone models of Parkinson’s dis-
ease. J Neurosci 23(34):10756–10764
Sigurdardottir LG, Markt SC, Sigurdsson S, Aspelund T, Fall K, 
Schernhammer E, Rider JR, Launer L, Harris T, Stampfer MJ, 
Gudnason V, Czeisler CA, Lockley SW, Valdimarsdottir UA, 
Mucci LA (2016) Pineal gland volume assessed by MRI and its 
correlation with 6-sulfatoxymelatonin levels among older men. 
J Biol Rhythms 31(5):461–469. https ://doi.org/10.1177/07487 
30416 65694 8
Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model 
of Parkinson’s disease. Neurotox Res 11(3–4):151–167
Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP (2011) Mela-
tonin or silymarin reduces maneb-and paraquat-induced Parkin-
son’s disease phenotype in the mouse. J Pineal Res 50(2):97–109
Skene DJ, Arendt J (2006) Human circadian rhythms: physiological 
and therapeutic relevance of light and melatonin. Ann Clin Bio-
chem 43(5):344–353
Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slo-
minski AT (2012) Melatonin membrane receptors in periph-
eral tissues: distribution and functions. Mol Cell Endocrinol 
351(2):152–166
Su L-Y, Li H, Lv L, Feng Y-M, Li G-D, Luo R, Zhou H-J, Lei X-G, Ma 
L, Li J-L (2015) Melatonin attenuates MPTP-induced neurotox-
icity via preventing CDK5-mediated autophagy and SNCA/α-
synuclein aggregation. Autophagy 11(10):1745–1759
Sun X, Ran D, Zhao X, Huang Y, Long S, Liang F, Guo W, Nucifora 
FC, Gu H, Lu X (2016) Melatonin attenuates hLRRK2-induced 
sleep disturbances and synaptic dysfunction in a Drosophila 
model of Parkinson’s disease. Mol Med Rep 13(5):3936–3944
Tamtaji OR, Mirhosseini N, Reiter RJ, Azami A, Asemi Z (2019a) Mel-
atonin, a calpain inhibitor in the central nervous system: current 
status and future perspectives. J Cell Physiol 234(2):1001–1007
Tamtaji OR, Mirhosseini N, Reiter RJ, Behnamfar M, Asemi Z (2019b) 
Melatonin and pancreatic cancer: current knowledge and future 
perspectives. J Cell Physiol 234(5):5372–5378
Tamtaji OR, Taghizadeh M, Kakhaki RD, Kouchaki E, Bahmani F, 
Borzabadi S, Oryan S, Mafi A, Asemi Z (2019c) Clinical and 
metabolic response to probiotic administration in people with 
Parkinson’s disease: a randomized, double-blind, placebo-con-
trolled trial. Clin Nutr 38(3):1031–1035
Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, 
Sainz RM, Reiter RJ (2003) Melatonin: a hormone, a tissue fac-
tor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal 
Res 34(1):75–78
Tan DX, Zanghi BM, Manchester LC, Reiter RJ (2014) Melatonin 
identified in meats and other food stuffs: potentially nutritional 
impact. J Pineal Res 57(2):213–218
Tan DX, Hardeland R, Back K, Manchester LC, Alatorre-Jimenez MA, 
Reiter RJ (2016) On the significance of an alternate pathway 
Cellular and Molecular Neurobiology 
1 3
of melatonin synthesis via 5-methoxytryptamine: comparisons 
across species. J Pineal Res 61(1):27–40
Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell 
M, Marras C, Bhudhikanok GS, Kasten M, Chade AR (2011) 
Rotenone, paraquat, and Parkinson’s disease. Environ Health 
Perspect 119(6):866
Thanvi B, Lo T (2004) Long term motor complications of levodopa: 
clinical features, mechanisms, and management strategies. Post-
grad Med J 80(946):452–458
Thiele SL, Warre R, Nash JE (2012) Development of a unilaterally-
lesioned 6-OHDA mouse model of Parkinson’s disease. J Vis 
Exp. https ://doi.org/10.3791/3234
Thomas B, Mohanakumar KP (2004) Melatonin protects against oxi-
dative stress caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydro-
pyridine in the mouse nigrostriatum. J Pineal Res 36(1):25–32
Torres-Farfan C, Rocco V, Monso C, Valenzuela F, Campino C, 
Germain A, Torrealba F, Valenzuela G, Seron-Ferre M (2006) 
Maternal melatonin effects on clock gene expression in a nonhu-
man primate fetus. Endocrinology 147(10):4618–4626
Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D (2008) 
Neuropathy as a potential complication of levodopa use in Par-
kinson’s disease. Mov Disord 23(13):1850–1859
Venkatesh VG, Rajasankar S, Swaminathan WJ, Prabu K, Ramku-
mar M (2019) Antiapoptotic role of Agaricus blazei extract in 
rodent model of Parkinson’s disease. Front Biosci (Elite edition) 
11:12–19
Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri 
F, Yang L, Beal MF, Andersen JK (2001) Caspase-9 activation 
results in downstream caspase-8 activation and bid cleavage in 
1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkin-
son’s disease. J Neurosci 21(24):9519–9528
von Gall C, Weaver DR, Moek J, Jilg A, Stehle JH, Korf HW (2005) 
Melatonin plays a crucial role in the regulation of rhythmic clock 
gene expression in the mouse pars tuberalis. Ann NY Acad Sci 
1040(1):508–511
Waldhauser F, Weiszenbacher G, Tatzer E, Gisinger B, Waldhauser 
M, Schemper M, Frisch H (1988) Alterations in nocturnal 
serum melatonin levels in humans with growth and aging. J 
Clin Endocrinol Metab 66(3):648–652. https ://doi.org/10.1210/
jcem-66-3-648
Wang JZ, Wang ZF (2006) Role of melatonin in Alzheimer-like neuro-
degeneration 1. Acta Pharmacol Sin 27(1):41–49
Wang SF, Yen JC, Yin PH, Chi CW, Lee HC (2008) Involvement of 
oxidative stress-activated JNK signaling in the methampheta-
mine-induced cell death of human SH-SY5Y cells. Toxicology 
246(2–3):234–241. https ://doi.org/10.1016/j.tox.2008.01.020
Wang Y, Lv D, Liu W, Li S, Chen J, Shen Y, Wang F, Hu L-F, Liu 
C-F (2018) Disruption of the circadian clock alters antioxidative 
defense via the SIRT1-BMAL1 pathway in 6-OHDA-induced 
models of Parkinson’s disease. Oxid Med Cell Longev 
2018:4854732
Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J (2006) Mela-
tonin attenuates diabetes-induced oxidative stress in rabbits. J 
Pineal Res 40(2):168–176
Wu YH, Swaab DF (2005) The human pineal gland and melatonin 
in aging and Alzheimer’s disease. J Pineal Res 38(3):145–152
Xia XG, Harding T, Weller M, Bieneman A, Uney JB, Schulz JB 
(2001) Gene transfer of the JNK interacting protein-1 protects 
dopaminergic neurons in the MPTP model of Parkinson’s dis-
ease. Proc Natl Acad Sci 98(18):10433–10438
Yamada M, Kida K, Amutuhaire W, Ichinose F, Kaneki M (2010) Gene 
disruption of caspase-3 prevents MPTP-induced Parkinson’s dis-
ease in mice. Biochem Biophys Res Commun 402(2):312–318
Yang X, Yang Y, Fu Z, Li Y, Feng J, Luo J, Zhang Q, Wang Q, Tian 
Q (2011) Melatonin ameliorates Alzheimer-like pathological 
changes and spatial memory retention impairment induced by 
calyculin A. J Psychopharmacol 25(8):1118–1125
Yildirim FB, Ozsoy O, Tanriover G, Kaya Y, Ogut E, Gemici B, Dil-
mac S, Ozkan A, Agar A, Aslan M (2014) Mechanism of the 
beneficial effect of melatonin in experimental Parkinson’s dis-
ease. Neurochem Int 79:1–11
Zampol MA, Barros MH (2018) Melatonin improves survival and res-
piratory activity of yeast cells challenged by alpha-synuclein and 
menadione. Yeast 35(3):281–290
Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero 
I, Vidal L, Hoenicka J, Rodriguez O, Atarés B (2004) The new 
mutation, E46K, of α-synuclein causes parkinson and Lewy body 
dementia. Ann Neurol 55(2):164–173
Zawilska JB, Skene DJ, Arendt J (2009) Physiology and pharmacology 
of melatonin in relation to biological rhythms. Pharmacol Rep 
61(3):383–410
Zucca FA, Segura-Aguilar J, Ferrari E, Muñoz P, Paris I, Sulzer D, 
Sarna T, Casella L, Zecca L (2017) Interactions of iron, dopa-
mine and neuromelanin pathways in brain aging and Parkinson’s 
disease. Prog Neurobiol 155:96–119
Zuch CL, Nordstroem VK, Briedrick LA, Hoernig GR, Granholm AC, 
Bickford PC (2000) Time course of degenerative alterations in 
nigral dopaminergic neurons following a 6-hydroxydopamine 
lesion. J Comp Neurol 427(3):440–454
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
